Format

Send to

Choose Destination
Immunotherapy. 2015;7(11):1213-27. doi: 10.2217/imt.15.87. Epub 2015 Oct 29.

Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Author information

1
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
2
Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Abstract

AIM:

We performed a meta-analysis of the risk of selected gastrointestinal toxicities associated with immune checkpoint inhibitors.

PATIENTS & METHODS:

Eligible studies included randomized trials of patients with solid tumors on ipilimumab, nivolumab, pembrolizumab, tremelimumab, pidilizumab and atezolizumab, describing events of diarrhea, vomiting or colitis.

RESULTS:

After exclusion of ineligible studies, a total of ten clinical trials were considered eligible for the meta-analysis. The relative risk of all-grade diarrhea, vomiting and colitis was 1.64 (95% CI: 1.19-2.26; p = 0.002), 0.72 (95% CI: 0.49-1.07; p = 0.1), 10.35 (95% CI: 5.78-18.53; p < 0.00001), respectively.

CONCLUSION:

Our meta-analysis has demonstrated that immune checkpoint inhibitors are associated with a significantly increased risk of all grade and high-grade colitis.

KEYWORDS:

colitis; diarrhea; ipilimumab; nivolumab

PMID:
26513491
DOI:
10.2217/imt.15.87
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center